Technical Analysis for CLVS - Clovis Oncology, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 5.66 | 1.98% | 0.11 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical CLVS trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | 1.98% | |
Wide Bands | Range Expansion | 1.98% | |
Oversold Stochastic | Weakness | 1.98% | |
Fell Below 200 DMA | Bearish | -1.05% | |
New Downtrend | Bearish | -1.05% | |
Wide Bands | Range Expansion | -1.05% | |
Oversold Stochastic | Weakness | -1.05% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
10 DMA Resistance | about 7 hours ago | |
200 DMA Resistance | about 8 hours ago | |
60 Minute Opening Range Breakout | about 9 hours ago | |
Rose Above Previous Day's High | about 9 hours ago | |
Up 5% | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/23/2021
Clovis Oncology, Inc. Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Disease Chemical Compounds Organic Compounds Gastrointestinal Drug Discovery Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Non Small Cell Lung Cancer Adp Epidermal Growth Factor Receptor Lung Cancer Treatment Of Non Small Cell Lung Cancer Gastrointestinal Stromal Tumor Lactams Indoles Foundation Medicine Heterocyclic Compounds
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.1 |
52 Week Low | 3.62 |
Average Volume | 8,712,111 |
200-Day Moving Average | 6.04 |
50-Day Moving Average | 6.57 |
20-Day Moving Average | 7.28 |
10-Day Moving Average | 6.06 |
Average True Range | 0.68 |
ADX | 22.91 |
+DI | 24.22 |
-DI | 24.70 |
Chandelier Exit (Long, 3 ATRs ) | 9.05 |
Chandelier Exit (Short, 3 ATRs ) | 7.55 |
Upper Bollinger Band | 10.35 |
Lower Bollinger Band | 4.21 |
Percent B (%b) | 0.24 |
BandWidth | 84.26 |
MACD Line | -0.42 |
MACD Signal Line | -0.16 |
MACD Histogram | -0.2582 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.48 | ||||
Resistance 3 (R3) | 6.52 | 6.29 | 6.34 | ||
Resistance 2 (R2) | 6.29 | 6.08 | 6.27 | 6.30 | |
Resistance 1 (R1) | 5.98 | 5.95 | 6.13 | 5.93 | 6.25 |
Pivot Point | 5.75 | 5.75 | 5.83 | 5.72 | 5.75 |
Support 1 (S1) | 5.43 | 5.54 | 5.59 | 5.39 | 5.07 |
Support 2 (S2) | 5.20 | 5.41 | 5.18 | 5.02 | |
Support 3 (S3) | 4.89 | 5.20 | 4.98 | ||
Support 4 (S4) | 4.84 |